Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Bioregulators
Khavinson short peptide bioregulator targeting thymus / immune cells.
Peptide B
Immune
Thymic peptide with broad immunomodulatory activity, approved in over 35 countries.
Typical vial
20 mg
Typical dose
1,000-5,000 mcg
Half-life
Short (minutes); biological effect persists via gene-expression modulation
FDA status
Not FDA approved.
Typical vial
5 mg
Typical dose
1000-1600 mcg
Half-life
~2 hours
FDA status
Not FDA approved. Granted orphan drug designation for hepato…
Crystagen effects
Thymosin Alpha-1 effects
Crystagen side effects
Thymosin Alpha-1 side effects
Crystagen dosing ranges
Immune support
1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year
Thymosin Alpha-1 dosing ranges
Immune modulation
1000-1600 mcg · Twice weekly (SubQ) · 6-12 months
Hepatitis treatment (clinical protocol)
1600 mcg · Twice weekly · 6-12 months
Acute immune support
1600 mcg · Daily for initial phase, then twice weekly · 2-4 weeks acute, then maintenance
Crystagen: Khavinson short peptide bioregulator targeting thymus / immune cells. Typical dose 1,000-5,000 mcg. Thymosin Alpha-1: Thymic peptide with broad immunomodulatory activity, approved in over 35 countries. Typical dose 1000-1600 mcg. Both fall under the Bioregulators and Immune categories.
Stacking Crystagen with Thymosin Alpha-1 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
Crystagen is typically dosed: Once daily (SubQ) or sublingual for Immune support. Thymosin Alpha-1 is typically dosed: Twice weekly (SubQ) for Immune modulation; Twice weekly for Hepatitis treatment (clinical protocol); Daily for initial phase, then twice weekly for Acute immune support.
Crystagen: Not FDA approved. Thymosin Alpha-1: Not FDA approved. Granted orphan drug designation for hepatocellular carcinoma and hepatitis B. Multiple clinical trials conducted but no NDA submitted.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free